06 March 2014 / International
Debiopharm Group™ to Acquire Products or Companies to Expand Activities at Manufacturing Facility in Martigny (Valais, Switzerland) [Read more]
05 March 2014 / International
Immunexpress Closes USD 6 Million Financing Round led by Debiopharm Group™ [Read more]
05 March 2014 / diagnostics
Immunexpress Closes USD 6 Million Financing Round led by Debiopharm Group™ [Read more]
06 March 2014
Debiopharm Group™ to Acquire Products or Companies to Expand Activities at Manufacturing Facility in Martigny (Valais, Switzerland) [Read more]
05 March 2014
Immunexpress Closes USD 6 Million Financing Round led by Debiopharm Group™ [Read more]
13 January 2014
Debiopharm Group™ Announces Completion of Recruitment for Phase III Clinical Study with Triptorelin 22.5 mg in Central Precocious Puberty [Read more]
24 September 2013
Debiopharm Group™ inaugure la « Debiopharm academy » à l’EPFL avec une première conférence sur la médecine personnalisée [Read more]
20 September 2013
Debiopharm Group™ a le plaisir d’annoncer les étudiants choisis pour les Bourses d’excellence [Read more]
17 September 2013
Debiopharm Investment SA entre dans le capital de la start-up de l’EPFL Smallrivers SA, éditeur du service Paper.li [Read more]
23 October 2013
A drug combination screen identifies taxanes as synergistic agents with the oral IAP inhibitor Debio 1143 in non-small cell lung cancer cells [Read more]
08 March 2013
Preclinical rationale for combining the Smac-mimetic Debio 1143 with concurrent chemioradiotherapy in LA-SCCHN [Read more]
01 June 2012
A Phase I study of Debio 0932, an oral HSP90 inhibitor, in patients with solid tumors [Read more]
